What AbbVie's latest 10-Q says: 10 signals
AbbVie filed its latest 10-Q with the SEC on Aug 3, 2026. It discusses acquisition announced, capex increase and data investment.
Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn
- Filed
- Aug 3, 2026
- Filings
- 2
- Signals
- 22
10-Q · latest 10
What AbbVie's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 10 signals
AbbVie secures $10B loan facility for proposed acquisition of Apogee
AbbVie has entered a $10 billion term loan facility to finance the future acquisition of Apogee.
$10B
364-day senior unsecured term loan facility for proposed acquisition of Apogee
AbbVie pays $650M upfront in R&D licensing deal with RemeGen, boosting R&D spend 15%
As part of a 15% YTD increase in R&D spending to $4.8B, AbbVie made a $650 million upfront payment for a licensing agreement with RemeGen.
$650M
Upfront charge for license agreement with RemeGen Co., Ltd.
15%
YTD increase in R&D expenses
Imbruvica global revenues plummet 29% in Q2 due to unfavorable pricing
A key product, Imbruvica, is facing significant headwinds, with revenues dropping 29% due to pricing pressure and lower demand.
29%
Decrease in Imbruvica global revenues for the three months ended June 30, 2026
AbbVie's Vyalev revenue grows over 100% due to strong market share uptake
The hyper-growth of Vyalev, with revenue increasing over 100% in the last six months, indicates a highly successful product launch.
100%
Revenue growth for Vyalev (greater than 100%)
Rising litigation reserve charges are negatively impacting SG&A expenses
The company reported that higher charges for litigation reserves are a significant headwind, partially offsetting gains from revenue growth.
AbbVie's R&D spending increased 15% to $4.8B to support its drug pipeline.
The 15% year-over-year increase in R&D expenses to $4.8 billion for the first half of the year is to support all stages of the company's pipeline.
$4.8B
R&D expenses for the six months ended June 30, 2026
15%
Year-over-year increase in R&D expenses for the six-month period
RemeGen Co., Ltd.Gubra A/SADARx Pharmaceuticals, Inc.Genentech Inc.
Botox Cosmetic sales up 10% YTD, driven by international market demand
Growth in the key Aesthetics portfolio is being driven by international markets, with Botox Cosmetic sales growing 10% in the first half of the year.
10%
Six-month revenue growth for Botox Cosmetic
Capital expenditures increased 16% YoY to $587M in H1 2026
AbbVie increased its capital expenditures by 16% year-over-year to $587 million for the first six months of 2026.
$587M
Capital expenditures for the six months ended June 30, 2026
16%
Year-over-year increase in capital expenditures for the six months ended June 30
- SEC EDGAR
10-Q
Filed · 12 signals
AbbVie's revenue base restructures as flagship drug Humira sees sales drop 40%
A 40% year-over-year revenue decline for the former blockbuster drug Humira, due to direct biosimilar competition, is forcing a fundamental restructuring of the company's revenue portfolio.
-40%
Year-over-year decrease in Humira net revenues for the quarter
Humira revenue plummets 40% in Q1 due to direct biosimilar competition
AbbVie's flagship drug, Humira, experienced a 40% revenue decline following its loss of exclusivity.
-40%
YoY decrease in Humira net revenues for the three months ended March 31, 2026
Showing 10 of 22 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
AbbVie earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Committing $10 billion in US capital investments over next 10 yearsAbbVie is making a massive, long-term investment in its US manufacturing and R&D infrastructure, with construction already underway. This signals significant budget for construction, engineering, advanced manufacturing equipment, and related technology solutions. | |
| Preparing for multiple new product approvals and indication expansionsAbbVie has a series of new product approvals (tavapadon, PVEK) and expanded indications (Rinvoq, Epkinly) expected over the next two years. These launches trigger spending on marketing automation, commercial analytics, sales training, and supply chain management solutions. | |
| Investing in consumer campaigns to drive patient activation in aestheticsTo combat market softness, AbbVie is launching new direct-to-consumer campaigns for BOTOX and fillers. This indicates an active budget and strategic focus on marketing, digital advertising, consumer data platforms, and technologies that can stimulate category growth and improve patient engagement. | |
| Raising full-year 2025 financial guidance for the third timeStrong business momentum has led to another increase in full-year revenue and EPS guidance. This financial outperformance indicates the company has ample resources and confidence to fund strategic initiatives and new technology investments. | |
| Navigating IRA price negotiations and global pricing pressuresThe company is actively engaged with the administration on drug pricing, has concluded IRA negotiations for key drugs, and is adjusting its international pricing strategy. This regulatory pressure creates a need for sophisticated pricing, market access, and government affairs consulting and analytics. | |
| Investing in advanced R&D platforms like bispecific ADCs and in vivo CAR-TThe company is building its future pipeline on complex, data-intensive technologies like bispecific antibody-drug conjugates and in vivo CAR-T. This strategy requires significant, ongoing investment in bioinformatics, data management, and AI/ML platforms to support discovery and development. |
Signal API · MCP
Track AbbVie with the Signal API
One POST /v1/companies/enrich call with abbvie.com returns AbbVie 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about AbbVie 10-Q
When did AbbVie file its latest 10-Q?
What did AbbVie disclose in its latest 10-Q?
What did AbbVie say on its recent earnings calls?
Where can I read AbbVie's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .